July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
June 2026 in “Journal of health economics and outcomes research” June 2026 in “Journal of health economics and outcomes research” 1 citations
,
December 2025 in “Journal of the American Academy of Dermatology”
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
Metformin lowers gremlin-1 and improves insulin resistance in women with PCOS.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
65 citations
,
November 2004 in “Journal of the American Academy of Dermatology” Bimatoprost can cause excessive eyelash growth.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
9 citations
,
August 2006 in “American Journal of Psychiatry” A woman's hair loss stopped after she stopped taking lamotrigine, suggesting it might cause hair loss.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
August 2013 in “Hospital Pharmacy” Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.
July 2013 in “Journal of clinical & experimental dermatology research” Bimatoprost can help treat hair loss.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
22 citations
,
March 2017 in “Transplant Infectious Disease” Leflunomide successfully treated a rare skin condition in a liver transplant patient.
Baricitinib works better than methotrexate for severe alopecia areata.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
3 citations
,
July 2025 in “Obesity Facts” GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.
51 citations
,
May 2004 in “American journal of ophthalmology” Using topical prostaglandin F2α for glaucoma may cause loss of eyelash or eyebrow pigment.
January 2010 in “Yearbook of Dermatology and Dermatologic Surgery” Topical latanoprost and bimatoprost ophthalmic solutions don't help eyelash growth in patients with alopecia areata.
August 2025 in “Pharmaceutics” A new method improves betulin delivery and shows promise in cancer treatment.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
January 2011 in “Side effects of drugs annual” Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
16 citations
,
June 2017 in “JAMA Dermatology” Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.